Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir
- 1 January 2009
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (1) , 81-85
- https://doi.org/10.1128/aac.01177-08
Abstract
In vitro resistance to maribavir (MBV), a cytomegalovirus UL97 kinase inhibitor currently in clinical trials, is known to result from viral UL97 mutations that confer moderate to high-level resistance and UL27 mutations that confer low-level resistance. To add to the four reported UL27 mutations, cytomegalovirus isolates or strains were propagated under MBV. Four clinical isolates evolved UL27 mutations, which were first detected after 8 to 30 passages under drug selection. In three separate experiments, laboratory strain T2294, which contained an exonuclease mutation, developed UL27 mutations at 10 to 12 passages under MBV. Most of these isolates and strains also developed a UL97 mutation, commonly T409M, before or after the appearance of the UL27 mutation. The passage of two laboratory strains genetically defective in UL97, in the absence of MBV, likewise resulted in UL27 mutations. The nine UL27 mutations observed included multiple instances of point, stop, and frameshift mutations, which were individually transferred to a reference CMV strain and which were shown to confer two- to threefold increases in MBV inhibitory concentrations. In contrast, seven common UL27 amino acid changes found in baseline clinical isolates conferred no MBV resistance. The mutants with UL27 mutations had slightly attenuated growth. The frequent mutation of UL27 suggests that its normal expression is mildly disadvantageous to the virus in the absence of UL97 kinase activity, whether the latter results from MBV inhibition or a genetic defect. Although the function of UL27 is unknown, it does not appear to be a direct antiviral target for MBV.Keywords
This publication has 21 references indexed in Scilit:
- Human cytomegalovirus interferes with signal transducer and activator of transcription (STAT) 2 protein stability and tyrosine phosphorylationJournal of General Virology, 2008
- Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging studyBlood, 2008
- Human Cytomegalovirus UL97 Kinase Activity Is Required for the Hyperphosphorylation of Retinoblastoma Protein and Inhibits the Formation of Nuclear AggresomesJournal of Virology, 2008
- Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavirReviews in Medical Virology, 2008
- Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II MutantJournal of Virology, 2008
- Human Cytomegalovirus Protein Kinase UL97 Forms a Complex with the Tegument Phosphoprotein pp65Journal of Virology, 2007
- Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir ResistanceThe Journal of Infectious Diseases, 2007
- Effect of Cell Culture Conditions on the Anticytomegalovirus Activity of MaribavirAntimicrobial Agents and Chemotherapy, 2006
- The Human Cytomegalovirus UL44 Protein Is a Substrate for the UL97 Protein KinaseJournal of Virology, 2003
- Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l -Riboside with a Unique Mode of ActionAntimicrobial Agents and Chemotherapy, 2002